key: cord-0922649-odmpfaaa authors: Kaffash Farkhad, Najmeh; Mahmoudi, Ali; Mahdipour, Elahe title: Regenerative therapy by using Mesenchymal Stem Cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms date: 2022-03-22 journal: Regen Ther DOI: 10.1016/j.reth.2022.03.006 sha: 53d77390ead6780d4c38e4937363948f7852892e doc_id: 922649 cord_uid: odmpfaaa COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), started in December 2019 in Wuhan, China, and quickly became the global pandemic. The high spread rate, relatively high mortality rate, and the lack of specific medicine have led researchers and clinicians worldwide to find new treatment strategies. Unfortunately, evidence shows that the virus-specific receptor Angiotensin-Converting Enzyme 2 (ACE-2) is present on the surface of most cells in the body, leading to immune system dysfunction and multi-organ failure in critically ill patients. In this context, the use of Mesenchymal Stem Cells (MSCs) and their secret has opened new therapeutic horizons for patients due to the lack of ACE2 receptor expression. MSCs exert their beneficial therapeutic actions, particularly anti-inflammatory and immunomodulatory properties, mainly through paracrine effects which are mediated by exosomes. Exosomes are bilayer nanovesicles that carry a unique cargo of proteins, lipids and functional nucleic acids based on their cell origin. This review article aims to investigate the possible role of exosomes and the underlying mechanism involved in treating COVID-19 disease based on recent findings. other cells in the body, do not express ACE2 receptors (12) . Currently, several clinical trials have been registered on the applications of exosomes (13) in the treatment of COVID-19 patients (https://clinicaltrials. gov), but only a limited number of them have been published (8) . The purpose of this review article is to explore the possible role of exosomes in the pathogenesis of COVID-19 and to discuss the potentials of MSC-derived exosomes in the treatment of COVID-19 patients. Exosomes are a subclass of extracellular vehicles (EVs) with a size range of 40-150 nm. They are formed by inward budding of the late endosomes and released following the multivesicular bodies (MVBs) fusion with the plasma membrane (14) . They were discovered during the investigation of sheep reticulocytes maturation in the 1980s and have rapidly attracted remarkable attention from researchers worldwide as a critical player of cell-to-cell communication (15) . Initially, they were considered to act as unwanted protein scavengers. (16) . However, exosomes are much more attractive because of their ability to stimulate immune responses both in-vivo (17, 18) and in-vitro (19, 20) . It has been proved that exosomes to be secreted from almost all cells in the body; moreover, they are abundant in body fluids such as plasma, breast milk, serum, menstrual blood, saliva, urine, malignant ascites, cerebral, and amniotic fluids (21) (22) (23) (24) (25) . Ultracentrifugation and high-performance liquid chromatography (HPLC) are common methods for exosomes isolation (26) , and western blotting, enzyme-linked immunosorbent assay (ELISA), flow cytometric analysis, nanoparticle tracking analysis, scanning electron microscopy as well as atomic force microscopy are common methods of identification and characterization of exosomes (26) (27) (28) . Based on their cellular origins, exosomes have an enriched and diverse cargo profile, including lipids, proteins, DNAs and RNAs, with specific functions such as regulating immune responses J o u r n a l P r e -p r o o f and cell-to-cell communications (29, 30) . These specific components make exosomes distinguishable from other microvesicles. For example, having various membrane proteins such as Alix, TSG101, Rab5, Rab 27a, Rab27b, and multiple tetraspanins (e.g., CD37, CD63, CD81, CD82) differentiate exosomes from apoptotic bodies (31) . In addition, transported exosomal mRNAs or miRNAs from donor cells can potentially change the fate of recipient cells. For instance, glioblastoma cell-derived exosomes were taken up by recipient endothelial cells and led to elevated tubule formation potentials in them (32) . The miRNA profile of exosomes produced by regulatory T cells, downregulated the inflammatory pathways in recipient cells (33) . Mesenchymal Stem Cells (MSCs) are non-hematopoietic multipotent cells characterized by selfrenewal potential and multi-lineage differentiation abilities. Researchers and clinicians have widely considered these cells in recent years due to their special biological features (34) . They are non-or low immunogenic, easily accessible, and have been isolated from various tissues such as bone marrow (35, 36) , menstrual-blood (24, 25) , umbilical cord (37), adipose tissues (38) , periodontal ligament (39) , and Wharton's Jelly (40) . MSCs home in the injured tissues and help the tissue regeneration by releasing abundant cytokines and mediators and/ or through differentiation and replacement of the damaged cells. MSCs regulate the inflammatory responses (41) . MSC-derived exosomes represent the MSCs-paracrine effects and exert similar biological functions of MSCs (8, 42) . For example, it has been shown that both MSCs and MSC-derived exosomes have neuroprotective effects (43) . MSC-derived exosomes could alleviate the endotoxin-induced acute lung injury in animal models (44) , similar to MSCs (45). In the same These exosomes contained miR-16 that downregulated the expression of vascular endothelial growth factor (VEGF) (46) . MSC-derived exosomes express the MSC-related antigens and adhesion molecules such as CD29, CD44, and CD73 (47) . Besides, it has been shown that the similar to MSCs, the MSC-derived exosomes contain a unique genetic information required for different signaling pathways such as angiogenesis or adipogenesis (48) . MSC therapy is a promising approach for treating various diseases. However, currently, cell-free therapy by using exosomes has attracted more attention of researchers because of multiple reasons, including DMSO independent storage because of their strong membrane (49) , the ability to pass the blood-brain barrier (50) , coordination with the immune system even in immune-privileged sites (51) , decreased risks of trapping in the lung due to their migration ability to the target cells which made them a good candidate for aerosol inhalation applications (52) , declined risk of tumor formation because of non-proliferative properties, and the lower membrane-bound protein contents with a lower risk of induction immune responses in comparison with their cell sources (51) . Indeed, it is now revealed that the beneficial therapeutic effects of MSCs are based on their soluble factors with paracrine and endocrine effects (53) . Viruses have many mechanisms to escape the immune system and to survive. Sequential mutations in the viruses' genome, similar to what is seen in the SARS-COV-2 today, and the multiple antigens expression are reasons that make it challenging to overcome viral diseases (54) . (55) . They found that hucMSCs-Exo was were able to target the hepatitis C virus replication and prevent the infection. They also suggested that these antiviral effects may have been mediated by a set of miRNAs transmitted by exosomes, particularly miR-221, miR-145, miR-199a, and let-7f (55) . It was also identified that exosomes derived from human vaginal fluid had an inhibitory effect on the early steps of the HIV-1 life cycle protecting women against HIV-1 infection. In fact, mimicking the function of reverse transcriptase by exosomes was considered as the mechanism involved in this post-entry blocking process (56) . In the same direction, in a recent clinical trial using exosomes derived from Bone Marrow-MSCs, it was found that exosomes alleviated the SARS-COV-2 disease through their immunomodulatory properties. The results showed that exosomes could reduce the inflammatory responses, particularly cytokine storm formation, and increase the lymphocyte counts against the virus attack (8). These results suggest that exosomes could be a new beneficial therapeutic strategy against the COVID-19 disease. The pandemic caused by the SARS-COV-2, which causes COVID-19 disease, is undoubtedly one of the biggest challenges of the first half of the 21st century (41) . Unfortunately, it is about two years from the start of the COVID-19 pandemic; however, physicians and researchers worldwide are still looking for ways to save critically ill patients and no specific treatment has been found for it. Immune system dysfunction is common in COVID-19 disease, and the severity of uncontrolled immune responses is related to the infection rate. It is showed that the immune system of COVID-19 patients was inhibited in the early stages of the disease and became overactived, the conditioned called cytokine storm, in the final stages of the disease progression (57) . Indeed, in critically ill patients, cytokine storm leads to a vast range of morbidity and mortality. Activation of the inflammatory nuclear factor-kappa B (NF-kB) pathway and the subsequent secretion of large J o u r n a l P r e -p r o o f amounts of inflammatory cytokines (including Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), and Interferon-gamma (IFN-γ)) by the virus infected cells led to the formation of cytokine storm (58) . As a positive feedback, the cytokine storm caused more production of inflammatory cytokines and more activated immune cells (59) . The results from many clinical trials revealed that in severe COVID-19 patients, cytokine storm is followed by a lower number of T lymphocytes (both helper and suppressor T cells) (60, 61) . T regulatory cells (T reg) and memory T cells are the most decreased populations among T cells, while Naïve T cells are highly present during the SARS-COV-2 attack (62) . It was shown that the CD3+, CD4+, and CD8+ T cells in severe COVID-19 patients were remarkably lower than normal peoples, whereas T h17 cells, as an inflammatory T subset, had an increased number (63) . Not only T cell but neutrophils cell number also increased in COVID-19 disease and changes in their structures and functions were observed (64, 65) . It has been stated that as the disease progresses, the number of neutrophils increases that leads to severe inflammatory responses especially in lungs (66) . Excessive Neutrophil Extracellular Traps (NETs) formation or NETosis in response to viral attacks is another neutrophil-related exaggerated inflammatory response involved in the COVID-19 pathogenesis As mentioned above, the SARS-COV-2 uses the ACE2 receptor to enter its target cells. On the other hand, the abundant expression of this marker on the surface of cells in various body organs such as kidneys, liver, testes, heart, and lungs (68) has given this opportunity to virus to invade multiple organs resulting in multiorgan failure and severe complications in critically COVID-19 patients. ARDS as a general lung injury in severely ill patients with COVID-19 is caused by ACE2-dysregulation, and cytokine storm (69) . Increased vascular permeability and the reduced compliance leading to alveolar inflammatory damages were the characteristic features of ARDS J o u r n a l P r e -p r o o f (70) . A systematic review reported a 39% correlation between ARDS and the death rate in COVID- Besides, it has been shown that SARS-COV-2 could affect cardiomyocytes both in-vitro (72) and in-vivo (73) , leading to myocardial injuries and elevated levels of troponin T and N-terminal probrain natriuretic protein in most severely ill patients with COVID-19 (74) . A high level of ACE2 expression in the cardiac pericytes illustrates the susceptibility of the cardiac tissue to SARS-COV-2 infection (75) . Unfortunately, clinical trials have reported an increased mortality rate in COVID-19 patients with underlying cardiovascular diseases (76, 77) . Liver dysfunction is another common complication in critically ill patients with COVID-19. MSCs with immunomodulatory properties and differentiation abilities have been used in recent years to treat various diseases such as diabetes (88) , rheumatoid arthritis (89), amyotrophic lateral sclerosis (36) , systemic lupus erythematosus and musculoskeletal disorders (41, 90) . The COVID-19 virus does not invade MSCs as they do not express ACE2 receptor (12) . Therefore, many physicians and researchers around the world have performed multiple clinical trials to treat COVID-19 disease by using MSCs (41) . Table 1 shows a summary of results from these studies. Only one clinical study reported treatment related side effects such as heart failure and liver dysfunction, the rest of studies reported no treatment related serious side effects (Table 1) . Most studies showed satisfactory clinical effects following MSC-therapy. For example, it was displayed that one dose of UMSCs (2 ×10 6 cell/kg BW) significantly reduced the inflammatory biomarkers such as C-Reactive Protein (CRP) and IL-6 levels, while improved the lymphocyte number, oxygen saturation level, and lung lesions in severe COVID-19 patients (99) . However, it is noteworthy that most of these studies lacked a control group (Table 1) . As mentioned before, MSCs can migrate to the injured tissues and exert their beneficial effects through the paracrine pathway. For example, in ARDS and lung injury, MSCs migrated and trapped in the lungs and secreted anti-inflammatory cytokines, antimicrobial agents and growth factors (101) . Keratinocyte growth factor secreted by MSCs led to alveolar epithelial cell repair and proliferation via induction of matrix metalloproteinase-9 enzyme, granulocyte-macrophage colony-stimulating factor, and IL-1 receptor antagonist (102, 103) . Besides, MSCs regulated the over-active immune systems of COVID-19 patients via secretion of immune-modulators (104), inhibition of Th1 and Th17 proliferation (105) and suppression of dendritic cell activation (106) . Since exosomes are the major mediators of MSC effcets, their application to treat COVID-19 syndrom sounds very promissing. Based on their origin and environmental conditions, exosomes can have different functions in the body. In fact, exosomes have significant potentials in diagnosis and treatment of various diseases (107) (108) (109) (110) . On the other hand, exosomes may be involved in the pathogenesis of diseases and act as a double-edged sword. For example, evidence showed that MSC-exosomes were actively involved in tumorigenesis, angiogenesis, and metastasis (111, 112) . In contrast, the inhibitory role of these exosomes in tumor expansion have also been reported (113) (114) (115) . In viral diseases, exosomes can have a dual role in expanding or inhibiting viral infections. In the case of the HIV virus, for example, it has been shown that exosomes activated the latent reservoir of the virus. They facilitated the spread of the disease and affected the chronic inflammation (116, 117) . In the same direction , studies showed that some body fluids-derived exosomes such as exosomes- Table. 2. As shown in Table. 2, exosomes are effective in lung repair. Results obtained from an animal study revealed that MSC-derived exosomes potentially could alter the phenotype of alveolar macrophages (M1) toward an anti-inflammatory state (M2) with enhanced phagocytic activities. Macrophages treated with MSC-derived exosomes were able to reduce the alveolar inflammation in mice bearing the endotoxin-induced lung injuries (140) . Furthermore, another study has stated that MSC-exosomes acted as a TLR signaling mediator and enhanced the transfer of regulatory miR-451 to the macrophages, thereby ameliorating the TNF-α secretion and suppressing the excess inflammatory responses to the lung injury (141) . Exosomes derived from human amnion epithelial cells could suppress the activated neutrophils and T cells proliferation and decrease the percentage of interstitial macrophage in the lungs (127) . MSC-exosomes are also able to improve liver injuries via several mechanisms. Inhibition of collagen (type I/III) productions and the suppression of epithelial-mesenchymal transition of hepatocytes were two possible beneficial effects of hucMSCs-exosomes in promoting the liver functions and reducing the serum AST levels in mice with the CCL4-induced liver injury (130) . MicroRNA-125b overexpressed exosomes isolated from chorionic plate-derived mesenchymal stem cells promoted the liver functions by inhibiting the hedgehog signaling pathway (142) . In this regard, findings from another study similarly showed that hucMSCs-exosomes with glutathione peroxidase-1 activity inhibited the oxidative stress-induced apoptosis in liver cells and enhanced their proliferation and functions (143) . An animal study showed that exosomes derived from adipose stem cells significantly declined hepatic inflammation and necrosis (144) . Since liver complications are common in critically COVID-19 ill patients, exosomes with the abovementioned potentials may offer a promising treatment for COVID-19 patients. Cardioprotection is another crucial feature of exosomes demonstrated by various preclinical studies, making them good candidates for treating heart problems caused by SARS-COV-2. For instance, Wang et al., using a rat model of myocardial infarction, found that specific miRNAs, particularly miR-21 released by exosomes isolated from endometrium-derived MSCs, could have cardioprotective effects by enhancing cell survival and angiogenesis (145) . Exosome therapy in animals with ischemia-reperfusion injuries decreased the cardiomyocyte apoptosis and improved the heart functions (135) . In another study, using exosomes derived from bone marrow-MSCs, it was found that exosomes reduced the inflammation of myocardial tissue and induced M2 macrophage polarizations through the inhibition of the NF-kB pathway and activation of AKT1/ AKT2 signaling pathways (134) . Exosomes are also capable of ameliorating renal complications. Exosomes home in the damaged kidney and exert beneficial biological actions (137) . Intravenous injections of 100 µg hucMSCsexosomes alleviated the ischemic injuries in a murine AKI model. Treatment decreased the tubular epithelial cell apoptosis through miR-125b-5p-mediated inhibition of P53 expression (137) . Results from another study also showed that hucMSCs-exosomes were effective in recovering AKI induced by cisplatin, both in-vivo and in-vitro. Decreasing the oxidative stress levels, preventing cellular apoptosis, and enhancing cell proliferations were mentioned as underlying mechanisms (138) . COVID-19 disease caused by the SARS-COV-2 quickly became a global pandemic. Unfortunately, available treatments are complementary and there is no specific treatment for the disease so far. Thus, the discovery of new treatment strategies is a necessity of medical science at this juncture. As a subclass of extracellular vesicles, exosomes have various roles in regulating the J o u r n a l P r e -p r o o f immune system and restoring injured organs. Studies have shown that exosomes are promising candidates for COVID-19 treatment as well as their applications in the diagnosis and prognosis of the disease. Although limited clinical trials are underway, more studies are required to evaluate the efficacy of exosome therapy for COVID-19 disease. The authors declare no conflict of interest. A novel coronavirus from patients with pneumonia in China The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet Extracellular vesicles: biology and emerging therapeutic opportunities Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats Immunosuppressive effect of mesenchymal stem cell-derived exosomes on a concanavalin A-induced liver injury model Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem cells and development Presence of SARS-CoV-2 RNAs in Exosomes from COVID-19 Patients: Their Characterization and Prognostic Potential. Available at SSRN 3781643 Diverse effects of exosomes on COVID-19: A perspective of progress from transmission to therapeutic developments Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Advanced drug delivery reviews Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Gesicles: microvesicle "cookies" for transient information transfer between cells Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials Exosomes derived from septic mouse serum modulate immune responses via exosome-associated cytokines In vivo evidence for the contribution of peripheral circulating inflammatory exosomes to neuroinflammation Ovarian cancer derived PKR1 positive exosomes promote angiogenesis by promoting migration and tube formation in vitro Exosomes released by breast cancer cells under mild hyperthermic stress possess immunogenic potential and modulate polarization in vitro in macrophages Body fluid derived exosomes as a novel template for clinical diagnostics Identification and proteomic profiling of exosomes in human urine The particles of the embryonic cerebrospinal fluid: how could they influence brain development? Brain research bulletin Promising effects of exosomes isolated from menstrual blood-derived mesenchymal stem cell on wound-healing process in diabetic mouse model Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28 The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers MicroRNAcontaining T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells How Similar Are Human Mesenchymal Stem Cells Derived From Different Origins? A Review of Comparative Studies. Current stem cell research & therapy Breast Recurrence of Acute Myeloid Leukemia After Bone Marrow Transplantation: A Case Report About Myeloid Sarcoma of the Breast Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Experimental and therapeutic medicine Adipose tissue versus stem cell-derived small extracellular vesicles to enhance the healing of acute burns MiR-17 modulates osteogenic differentiation through a coherent feed-forward loop in mesenchymal stem cells isolated from periodontal ligaments of patients with periodontitis Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord Are Mesenchymal Stem Cells able to manage Cytokine Storm in COVID-19 patients? A review of recent studies Impaired bone regenerative effect of exosomes derived from bone marrow mesenchymal stem cells in type 1 diabetes. Stem cells translational medicine Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice Therapeutic effect of intravenous bone marrowderived mesenchymal stem cell transplantation on early-stage LPS-induced acute lung injury in mice. Nan fang yi ke da xue xue bao= Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells Exosomes derived from mesenchymal stem cells. International journal of molecular sciences MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem cells translational medicine Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio Exosomes for targeted siRNA delivery across biological barriers. Advanced drug delivery reviews Preclinical translation of exosomes derived from mesenchymal stem/stromal cells Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views Exosomes in viral disease Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection. Stem cells translational medicine Human vaginal fluid contains exosomes that have an inhibitory effect on an early step of the HIV-1 life cycle Immune suppression in the early stage of COVID-19 disease Into the eye of the cytokine storm COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal transduction and targeted therapy Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia Immune response, inflammation, and the clinical spectrum of COVID-19 Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections Dynamic changes of D-dimer and neutrophillymphocyte count ratio as prognostic biomarkers in COVID-19 Neutrophils and COVID-19: The road so far Excessive neutrophils and neutrophil extracellular traps in COVID-19 Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 A human homolog of angiotensinconverting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respiratory medicine Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert review of respiratory medicine SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options SARS-CoV-2: a potential novel etiology of fulminant myocarditis COVID-19 and the cardiovascular system Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients Acute kidney injury in the 2019 novel coronavirus disease. Kidney diseases COVID-19-associated kidney injury: a case series of kidney biopsy findings COVID-19-Associated Acute Kidney Injury: Learning from the First Wave Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan Kidney disease is associated with inhospital death of patients with COVID-19 Severe acute kidney injury in COVID-19 patients is associated with in-hospital mortality Kidney function on admission predicts in-hospital mortality in COVID-19 Multiple organ infection and the pathogenesis of SARS Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran Bone marrow concentrate (BMC) therapy in musculoskeletal disorders: evidence-based policy position statement of American Society of Interventional Pain Physicians (ASIPP) Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report Systemic administration of human umbilical cord-derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID-19 with multiple comorbidities: A case report Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Frontiers of medicine Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem cell research & therapy Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal transduction and targeted therapy Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal transduction and targeted therapy Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. The Lancet Respiratory Medicine Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. American journal of respiratory and critical care medicine Mesenchymal stem cells as living antiinflammatory therapy for COVID-19 related acute respiratory distress syndrome. World journal of stem cells Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells Exosomes: novel biomarkers for clinical diagnosis. The scientific world journal Exosomes as new diagnostic tools in CNS diseases Exosomes as drug delivery vehicles for Parkinson's disease therapy A comprehensive overview of exosomes as drug delivery vehicles-endogenous nanocarriers for targeted cancer therapy Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites BM mesenchymal stromal cellderived exosomes facilitate multiple myeloma progression Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem cells and development 245 MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1 Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef-and ADAM17-dependent mechanism Exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells Semen exosomes promote transcriptional silencing of HIV-1 by disrupting NF-κB/Sp1/Tat circuitry Exosomes in HIV infection Risk, diagnostic and predictor factors for classical hodgkin lymphoma in HIV-1-infected individuals: Role of plasma exosome-derived miR-20a and miR-21 TAX-mRNAcarrying exosomes from human T cell lymphotropic virus type 1-infected cells can induce interferongamma production in vitro Circulating exosomes are strongly involved in SARS-CoV-2 infection COVID-19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression Exosomes from COVID-19 Patients Carry Tenascin-C and Fibrinogen-β in Triggering Inflammatory Signals in Cells of Distant Organ Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair Exosomes released by bone marrow mesenchymal stem cells attenuate lung injury induced by intestinal ischemia reperfusion via the TLR4/NF-κB pathway Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem cells and development Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation Human umbilical cord MSC-derived exosomes suppress the development of CCl4-induced liver injury through antioxidant effect Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization Exosomes derived from mesenchymal stem cells rescue myocardial ischaemia/reperfusion injury by inducing cardiomyocyte autophagy via AMPK and Akt pathways. Cellular physiology and biochemistry Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/β-catenin signaling pathway Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. American journal of respiratory and critical care medicine Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by chorionic plate-derived mesenchymal stem cells hucMSC exosome-derived GPX1 is required for the recovery of hepatic oxidant injury Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Experimental & molecular medicine Enhanced cardioprotection by human endometrium mesenchymal stem cells driven by exosomal microRNA-21. Stem cells translational medicine We would like to thank Ms Heydari for her comments on figures.J o u r n a l P r e -p r o o f